BCAL Director Jayne Shaw Increases Shareholding via On-Market Purchase

An update from BCAL Diagnostics Limited ( (AU:BDX) ) is now available.

BCAL Diagnostics has disclosed a change in the interests of director Jayne Shaw, who increased her holding in the company through an on-market purchase of additional ordinary shares. The transaction, completed on 20 February 2026 for 192,000 shares at a total consideration of $23,615, modestly lifts her direct and indirect equity position in the diagnostics group.

The purchase underscores continued alignment between the director and shareholders, as Shaw maintains significant exposure to BCAL Diagnostics’ equity alongside existing share and option holdings. No interests in related contracts were reported to have changed, and the trade was conducted outside a closed period, indicating routine compliance with the company’s governance and disclosure obligations.

The most recent analyst rating on (AU:BDX) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.

More about BCAL Diagnostics Limited

BCAL Diagnostics Limited is an Australian healthcare company focused on diagnostic technologies, particularly in blood-based testing solutions. The business operates in the medical diagnostics sector and targets clinical markets where early and accurate disease detection can improve patient outcomes and inform treatment decisions.

Average Trading Volume: 320,565

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$42.33M

For a thorough assessment of BDX stock, go to TipRanks’ Stock Analysis page.